Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.
The structurally novel bifunctional ligands C-NETA and C-NE3TA, each possessing both acyclic and macrocyclic moieties, were prepared and evaluated as potential chelates for radioimmunotherapy (RIT) and targeted magnetic resonance imaging (MRI). Heptadentate C-NE3TA was fortuitously discovered during the preparation of C-NETA. An optimized synthetic method to C-NETA and C-NE3TA including purification of the polar and tailing reaction intermediates, tert-butyl C-NETA (2) and tert-butyl C-NE3TA (3) using semiprep HPLC was developed. The new Gd(III) complexes of C-NETA and C-NE3TA were prepared as contrast enhancement agents for use in targeted MRI. The T 1 relaxivity data indicate that Gd(C-NETA) and Gd(C-NE3TA) possess higher relaxivity than Gd(C-DOTA), a bifunctional version of a commercially available MRI contrast agent; Gd(DOTA). C-NETA and C-NE3TA were radiolabeled with (177)Lu, (90)Y, (203)Pb, (205/6)Bi, and (153)Gd; and in vitro stability of the radiolabeled corresponding complexes was assessed in human serum. The in vitro studies indicate that the evaluated radiolabeled complexes were stable in serum for 11 days with the exception being the (203)Pb complexes of C-NETA and C-NE3TA, which dissociated in serum. C-NETA and C-NE3TA radiolabeled (177)Lu, (90)Y, or (153)Gd complexes were further evaluated for in vivo stability in athymic mice and possess excellent or acceptable in vivo biodistribution profile. (205/6)Bi- C-NE3TA exhibited extremely rapid blood clearance and low radioactivity level at the normal organs, while (205/6)Bi- C-NETA displayed low radioactivity level in the blood and all of the organs except for the kidney where relatively high renal uptake of radioactivity is observed. C-NETA and C-NE3TA were further modified for conjugation to the monoclonal antibody Trastuzumab.
Chemistry Division, Biological, Chemical, and Physical Sciences Department, Illinois Institute of Technology, Chicago, Illinois 60616, USA. Chong@iit.edu
Hyun-Soon
HS
Chong
Hyun A
HA
Song
Xiang
X
Ma
Diane E
DE
Milenic
Erik D
ED
Brady
Sooyoun
S
Lim
Haisung
H
Lee
Kwamena
K
Baidoo
Dengfeng
D
Cheng
Martin W
MW
Brechbiel
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized; D003432:Cross-Linking Reagents / Q000138:chemical synthesis* / Q000378:metabolism* / Q000493:pharmacokinetics; D005998:Glycine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics; D006573:Heterocyclic Compounds, 1-Ring / Q000138:chemical synthesis* / Q000378:metabolism*; D006801:Humans; D017879:Isothiocyanates / Q000737:chemistry; D008024:Ligands; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D016499:Radioimmunotherapy / Q000379:methods*; D014018:Tissue Distribution; D000068878:Trastuzumab
C529856:(2-(4,7-biscarboxymethyl(1,4,7)triazacyclonona-1-yl-ethyl)carbonylmethylamino)acetic acid; C531333:(4-(2-(biscarboxymethylamino)-3-(4-nitrophenyl)propyl)-7-carboxymethyl(1,4,7)triazonan-1-yl)acetic acid; C531334:(4-carboxymethyl-7-(2-(carboxymethylamino)-3-(4-nitrophenyl)propyl)(1,4,7)triazonan-1-yl)acetic acid; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003432:Cross-Linking Reagents; D006571:Heterocyclic Compounds; D006573:Heterocyclic Compounds, 1-Ring; D017879:Isothiocyanates; D008024:Ligands; D000068878:Trastuzumab; D005998:Glycine